FDA approves 3rd drug for disease affecting spinal cord

Spine

The FDA has approved the third drug for the treatment of neuromyelitis optica spectrum disorder, which affects the optic nerves and spinal cord, according to an Aug. 17 news release.

Enspryng, the latest drug to hit the market, was shown to be a safe and effective treatment for NMOSD in two 96-week clinical trials.

"Until last year, there were no FDA-approved treatments for patients with this rare, debilitating and sometimes fatal disease. Now there are three," said Billy Dunn, MD, director of the office of neuroscience in the FDA's Center for Drug Evaluation and Research.

Enspryng was developed by Genentech, a biotechnology company that received FDA clearance for its Evrysdi drug for spinal muscular atrophy earlier this month.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers